Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Increasing outsourcing volume by large pharmaceutical companies

Large pharmaceutical sponsors expand access to commercial production through long-duration commitments to external manufacturing networks. In April 2025, Regeneron agreed to have FUJIFILM Biotechnologies (formerly FUJIFILM Diosynth Biotechnologies) manufacture bulk drug product for its commercial biologic medicines in Holly Springs, North Carolina, under a 10-year agreement.^[1] The arrangement was expected to nearly double Regeneron’s US large-scale manufacturing capacity. In February 2026, GSK renewed a 5-year manufacturing partnership with Bora Pharmaceuticals that expanded access to multiple Bora sites. GSK is the largest pharmaceutical partner at Bora’s Mississauga facility, where Bora provides end-to-end manufacturing for more than 20 commercial product lines. Together, these commitments show how outsourcing can anchor recurring commercial workloads, giving CDMOs a reason to organize capacity around sustained product supply instead of relying exclusively on development batches.

Surge in biologics and complex-molecule pipelines

Complex-therapy pipeline growth expands the potential customer base for specialized development services before programs reach commercial manufacturing. The ISCT/Citeline global cell and gene therapy pipeline contained 383 active clinical trials in its 2026 edition, compared with 322 in the 2025 edition. Phase I and II studies represented 95% of that 2026 clinical-trial pipeline. This concentration makes progression through clinical development a central condition for translating the larger trial population into commercial supply requirements. Development-stage sponsors offer the nearer service opportunity, because the trial mix supports clinical-development work before it supports commitments to commercial manufacturing suites.

Cost- and speed-advantage of manufacturing in emerging markets

For a pharmaceutical sponsor sourcing small-molecule generic tablets, an emerging-market CDMO’s potential advantage depends on the local cost of the required production standard. An Indian supplier would be cheaper if lower local labor and facility costs reduced the cost of an otherwise equivalent manufacturing assignment. Any saving would need to survive the buyer’s destination-market validation and release obligations. A speed advantage would likewise require the supplier to complete those obligations sooner, without treating a less demanding specification as an equivalent service. Price-sensitive generic assignments would favor suppliers that could preserve their local cost advantage after meeting the destination’s requirements.

Consolidation toward end-to-end one-stop CDMOs

Combining complementary capabilities can reduce organizational handoffs for sponsors seeking external support across several development and manufacturing stages. In September 2026, Kincell Bio and Cellipont Bioservices completed their merger to form Kincellis Advanced Therapies, a US CDMO spanning cell-therapy development through commercial supply.^[2] The combination joined immune-cell expertise with stem-cell and other advanced-modality capabilities. CordenPharma completed its AmbioPharm acquisition in August 2026, strengthening an offering extending from peptide drug substance to sterile injectable and oral solid drug products. Its announcement described integration of the acquired US and Chinese sites as planned over the following months. A peptide or cell-therapy program can stay with one organization from development through supply, with CordenPharma’s version depending on the announced integration of its acquired sites.

Stringent multi-region regulatory requirements

US-bound pharmaceutical batches can face import detention after manufacturing is completed. On February 12, 2025, FDA added India-based contract manufacturer Zenzi Pharmaceutical Industries Private Limited to Import Alert 66-79 for all drugs and drug products from the listed establishment. Zenzi remained on the Red List in the September 23, 2026 edition. The alert covers foreign establishments refusing FDA inspection or a mandatory remote regulatory assessment, and FDA divisions may detain covered shipments without physical examination. Release may be considered after case-by-case evaluation of evidence when shipments are detained. Export manufacturers with a listing like this face US entry as the point where an otherwise completed batch can stall, adding release-review delay after production.

Capacity-utilization and lead-time risk

Growing peptide programs can require additional manufacturing headroom as they advance. Medtide Inc., a peptide contract research, development, and manufacturing organization, reported high utilization across its production lines during the first 5 months of 2025. Its key lines comprised high-capacity synthesis lines and large-diameter purification lines, linking the constraint to specific production steps. In its June 2025 prospectus, the supplier warned that excessively high utilization risked losing potential orders because customers preferred sufficient buffered capacity.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market Segment Analysis

API manufacturing accounted for a 54.64% share of the pharmaceutical contract development and manufacturing organization (CDMO) market size in 2026. Cambrex Corporation’s Charles City, Iowa, site manufactures active pharmaceutical ingredients (APIs) and intermediates, including highly potent molecules and controlled substances. In October 2025, the company announced a planned USD 120 million investment to increase the site’s large-scale API manufacturing capacity by 40%, to nearly 1 million liters. In March 2026, Cambrex completed initial engineering studies for the new large-scale API plant at the site, progress toward the previously announced USD 120 million investment.

Finished dosage form (FDF) development and manufacturing is forecast to be the fastest-growing service segment, with a CAGR of 7.45% between 2027 and 2032. Ardena completed its acquisition of Catalent’s Somerset, New Jersey, facility in February 2025, adding late-stage and small-scale commercial oral drug manufacturing capabilities. A newer patient-oriented dosage-form assignment connects outsourced production directly to a planned product introduction. In August 2026, Cycle Pharmaceuticals agreed to have Forma Life Sciences manufacture FDA-approved CAVHANZA (nilotinib) orally disintegrating tablets in Irvine, California, to establish US commercial supply ahead of Cycle’s introduction. Product-specific supply preparation extends the FDF assignment from developing a dosage form to establishing a commercial manufacturing route for an approved therapy.

Small molecules represented a 61.35% pharmaceutical contract development and manufacturing organization (CDMO) market share in 2026. Lonza Group reported more than 135 commercial small molecules in its 2025 Advanced Synthesis portfolio, covering APIs, highly potent APIs, dosage forms and delivery systems, and particle engineering. It also signed a large multiyear commercial small-molecule drug-substance supply agreement in 2025.

High-potency APIs are forecast to be the fastest-growing molecule segment, with a CAGR of 8.35% between 2027 and 2032. Aragen Life Sciences began operating its OneHP high-potency development and manufacturing platform at Nacharam in Hyderabad, India, on October 6, 2026. The platform operates one manufacturing line designed for annual API capacity of 500 to 600 kilograms and supports highly potent compounds, including cytotoxic molecules. It connects milligram-scale discovery with process development and multi-kilogram manufacturing under current good manufacturing practice (cGMP). Keeping those stages on one campus makes early process development part of the manufacturing relationship before a potent compound reaches larger batch requirements.

Solid oral products formed the largest dosage-form segment, accounting for 39.2% of CDMO revenue in 2026. In August 2025, Piramal Pharma Solutions, part of Piramal Pharma Ltd., opened a dedicated oral-solid-dose suite at Sellersville, Pennsylvania, for NewAmsterdam Pharma. Reconfigured existing space housed a suite designed for multilayer tablet production, with granulation, compression, tableting, and coating capabilities. It was intended to provide commercial capacity for NewAmsterdam’s investigational fixed-dose combination, with patient delivery conditional on approval. Piramal’s dedicated multilayer suite ties the manufacturing assignment to NewAmsterdam’s defined tablet configuration, extending the service proposition beyond access to general-purpose equipment.

Sterile injectables are forecast to be the fastest-growing dosage-form segment, with a CAGR of 9.3% between 2027 and 2032. In September 2026, CordenPharma projected capacity of up to 500 million injectable units annually at Caponago, Italy, serving programs from early-phase projects through large-scale commercial production. CordenPharma frames its planned Caponago capacity as serving injectable programs from early-phase projects through large-scale commercial production, so a program could scale within one supplier as volumes grow. Topicals and transdermals have a commercial-transfer role, illustrated by MedPharm’s October 2026 agreement with an unnamed global pharmaceutical company for a specialty topical product in Durham, North Carolina. Novel and specialty forms create formulation-development assignments, illustrated by InnoCore’s March 2026 collaboration with an unnamed US pharmaceutical company on a long-acting injectable small molecule for depression.

Oncology was the largest therapeutic-area segment, accounting for 32.24% of CDMO revenue in 2026. Lupin Manufacturing Solutions, a wholly owned subsidiary of Lupin Limited, commissioned a dedicated oncology API CDMO block at Vizag, India, in November 2025.^[3] The high-containment unit was designed to support oncology programs from preclinical research through commercial manufacturing, with a batch range of 1 to 35 kilograms. At commissioning, the unit had 20 reactors and more than 20 isolators, with containment systems designed for exposure levels of ≤0.05 µg/m³. Batch sizes of 1 to 35 kilograms inside a unit built to contain highly potent API production suit programs that move from preclinical to commercial batches.

Infectious diseases and vaccines are forecast to be the fastest-growing therapeutic-area segment, with a CAGR of 8.4% between 2027 and 2032. In March 2026, SK bioscience contracted IDT Biologika for drug-product development and manufacturing for MSD’s existing Zaire Ebola vaccine with an updated process. SK bioscience will produce the drug substance, and the updated process, developed with MSD and Hilleman Laboratories, aims to raise manufacturing yield and improve thermostability. AGC Biologics had separately agreed in July 2025 to supply drug substance from Heidelberg, Germany, for Phase II studies of Valneva’s investigational tetravalent Shigella bioconjugate vaccine. Vaccine assignments in this group range from re-engineering an existing product’s supply process to supplying clinical-candidate material.

Geography Analysis

North America Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market

North America accounted for a 37.88% share of the pharmaceutical contract development and manufacturing organization (CDMO) market size in 2026. FUJIFILM Biotechnologies’ Holly Springs site in North Carolina, United States, launched cGMP production in 2025 with 8 bioreactors of 20,000 liters each. One of North America’s largest end-to-end cell-culture facilities, it gives sponsors an external manufacturing option linked to substantial production assets within the region.

Asia-Pacific Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market

Asia-Pacific is forecast to be the fastest-growing geography, with a CAGR of 7.6% between 2027 and 2032. Aragen’s installed small-molecule capacity across Hyderabad and Visakhapatnam in India stood at 364,000 liters on March 31, 2026. In July 2026, AGC Biologics, an AGC Inc. subsidiary, entered a long-term agreement to provide commercial manufacturing at Yokohama, Japan, for multiple products of an unnamed global biopharmaceutical customer. At the announcement, the site was under development, with GMP-compliant services planned for 2027. The Japanese agreement illustrates a route to expansion in which a future service launch is backed by a customer commitment, rather than capacity construction alone.

Within Europe, the EU’s GMP guidance requires a written contract between the contract giver and contract acceptor for outsourced pharmaceutical activities. Aenova provides drug-product development, manufacturing, and packaging at sites in Germany, Switzerland, Italy, Ireland, and Romania. In the Middle East and Africa, Egypt’s SEDICO and Sandoz Global agreed in March 2025 to technology transfer for local manufacture of 5 essential oncology products. Porton Advanced Solutions and EVA Pharma signed a June 2025 memorandum of understanding to develop CAR-T manufacturing capabilities, with hubs planned in Egypt and Saudi Arabia. In South America, Anvisa’s August 2025 certification of Akums’ Haridwar, India, sterile facility authorized manufacture and export to Brazil, opening a route through qualified overseas production.

Regulatory Framework and Outlook

Selected jurisdictions are compared by the approvals, quality controls, and announced policy changes affecting pharmaceutical contract manufacturers. The perspective is a CDMO operating an affiliated network of equivalent units making the same drugs under one quality unit and a unified pharmaceutical quality system while serving pharmaceutical sponsors. FDA’s framework for finished pharmaceuticals gives quality-control units approval or rejection authority over components, packaging materials, labeling, and drugs. China’s National Medical Products Administration (NMPA) contract-manufacturing notice keeps marketing authorization holder (MAH) and manufacturer obligations distinct, making oversight allocation another part of the compliance task.

FDA’s July 13, 2026 proposal would simplify registration for this affiliated network, excluding separately hired unaffiliated contract manufacturers, but remained proposed on October 20, 2026 after comments closed on September 11, 2026. The European Commission’s documentation, computerized-system, and AI GMP drafts (July to October 2025 consultation) were unadopted on October 20, 2026 without implementation dates, suggesting heavier validation alongside Germany’s state-level authorization and GMP inspection. China’s enforcement schedule generally allows one year from December 30, 2025, for remediation, with reasons and completion deadlines required for longer items and consequences where regulator-set time limits are missed. Brazil’s quality-system duties under RDC 658/2022 continue, and conditional risk-based packaging flexibility took effect April 23, 2025, supporting continuity because Anvisa’s September 2026 sterile-GMP review announcement sets no revised text or effective date.

Value Chain Stages

Value capture differs across drug-substance production, sterile finished-dose manufacturing, and packaging and clinical-supply services. Cambrex Corporation provides drug-substance development, manufacturing, analytical, and investigational new drug application support services to pharmaceutical clients. Thermo Fisher Scientific Inc. (Patheon) develops and commercially manufactures sterile liquid and lyophilized products at Swindon in the United Kingdom. Across these stages, the purchased service changes from ingredient development to finished-dose execution and trial-supply preparation.

Patheon’s clinical-supply services connect drug manufacturing with packaging, labeling, and distribution for biotech and biopharma sponsors. Combining those assignments can reduce the handover work between a manufactured batch and trial supplies ready for distribution, extending the provider’s fee opportunity to packaging, labeling, and distribution. Execution responsibility broadens with fee capture, since the provider takes on packaging and distribution deliverables alongside the clinical batch.

Key Opportunities for Market Participants

Supplier opportunities depend on whether the buyer needs a facility operator, an improved manufacturing process, or additional productive capacity. BRIC-THSTI’s Faridabad mandate in India requires proven CAR-T experience and obliges the partner to procure and qualify additional equipment. Planned EU support targets eligible critical medicines with a demonstrated supply vulnerability and viable long-term supply to the Union market. The commercial distinction is between winning a manufacturing assignment and funding the capabilities needed to pursue subsequent customer work.

Faridabad is the only one of these openings that procures an operator for an existing facility. The UK competition and planned EU call instead fund projects that applicants must design and win through competitive selection. An operator’s documented CAR-T production history and equipment-qualification plan determine whether its bid addresses the Faridabad facility’s execution requirements.